Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.50 Consensus Price Target from Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have received an average recommendation of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and three have issued a strong buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $11.50.

Several equities analysts have recently commented on the company. Oppenheimer assumed coverage on Aclaris Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating and a $10.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research note on Thursday, March 19th. UBS Group set a $10.00 price target on Aclaris Therapeutics in a research note on Thursday, April 16th. Wedbush raised their price target on Aclaris Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Wednesday.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard sold 300,000 shares of Aclaris Therapeutics stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $4.53, for a total value of $1,359,000.00. Following the transaction, the insider owned 13,950,000 shares in the company, valued at $63,193,500. The trade was a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in shares of Aclaris Therapeutics by 1.7% during the first quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company’s stock worth $776,000 after purchasing an additional 3,507 shares during the period. Raymond James Financial Inc. lifted its holdings in Aclaris Therapeutics by 2.2% in the third quarter. Raymond James Financial Inc. now owns 283,476 shares of the biotechnology company’s stock valued at $539,000 after acquiring an additional 6,217 shares during the period. Rhumbline Advisers lifted its holdings in Aclaris Therapeutics by 7.4% in the third quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 6,271 shares during the period. ProShare Advisors LLC lifted its holdings in Aclaris Therapeutics by 45.4% in the fourth quarter. ProShare Advisors LLC now owns 21,553 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 6,734 shares during the period. Finally, Intech Investment Management LLC lifted its holdings in Aclaris Therapeutics by 19.8% in the fourth quarter. Intech Investment Management LLC now owns 46,646 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 7,702 shares during the period. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Price Performance

Shares of ACRS opened at $5.00 on Monday. The company has a market cap of $698.32 million, a PE ratio of -8.93 and a beta of 0.76. The business has a fifty day moving average of $4.53 and a 200 day moving average of $3.79. Aclaris Therapeutics has a 52-week low of $1.38 and a 52-week high of $5.15.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business had revenue of $2.00 million during the quarter, compared to the consensus estimate of $1.32 million. Aclaris Therapeutics had a negative return on equity of 55.89% and a negative net margin of 832.58%. As a group, research analysts anticipate that Aclaris Therapeutics will post -0.65 earnings per share for the current fiscal year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.